Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 13,749 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: Aspergillosis
Interventions: voriconazole, anidulafungin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 26
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 15 more

Conditions: Pain, Chronic Pain, Mental Disorders, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Arthritis
Interventions: Unblinded to Genetic Testing Results, Blinded to Genetic Testing Results; Other
Lead sponsor: Proove Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 31
States / cities: Beverly Hills, California • Fresno, California • La Jolla, California + 23 more

Conditions: Preterm Delivery, Inadequate Milk Production
Interventions: Merotocin, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: New Haven, Connecticut • South Bend, Indiana • Baltimore, Maryland + 7 more

Conditions: Thoracic Organ Transplantation
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 14 Years to 80 Years
Enrollment: 991 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2034
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Sleep, Physical Activity
Interventions: Go/No-Go Task, Delay discounting task, Mirror Tracing Persistence Task, Spatial Span, Stop Signal Task, Flanker task; Behavioral
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 8 Years to 12 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Neoplasms
Interventions: Gene-modified (GM) T cell therapy; Genetic
Lead sponsor: Celgene; Industry
Eligibility: Not listed
Enrollment: 1,541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2043
U.S. locations: 104
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 6
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Feasibility Studies
Interventions: PAVE intervention, Education control; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 55 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: ALXN1007, Placebo; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Tobacco Use
Interventions: Tobacco-free, Discrete, Convenient; Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 13 Years to 120 Years
Enrollment: 5,133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Drug Use Disorders During Pregnancy
Interventions: Usual RBT (t-RBT), Reduced RBT (r-RBT), Abbreviated RBT (a-RBT), Enhanced RBT (e-RBT), Early compliant t-RBT, Early non-compliant t-RBT, Early compliant r-RBT, Early non-compliant r-RBT; Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 46 Years · Female only
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
Interventions: COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1; Biological · Other
Lead sponsor: GeoVax, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Duarte, California • Baltimore, Maryland • Worcester, Massachusetts + 3 more

Conditions: Prostate Cancer, Sexual Dysfunction and Infertility
Interventions: finasteride, flutamide, quality-of-life assessment; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Male only
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2010
U.S. locations: 43
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 26 more

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Minimal (Trophic) Feeding, Full Feeding, Omega-3 Fatty Acids and Antioxidant Supplements, Placebo; Behavioral · Dietary Supplement
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 13 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 41
States / cities: Fresno, California • Sacramento, California • San Francisco, California + 20 more

Conditions: Chronic Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo; Drug · Other
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more

Conditions: HIV Infections
Interventions: Infant Formula; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 17 Days
Enrollment: 2,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 62
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more

Conditions: Melanoma (Skin)
Interventions: dasatinib; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 153
States / cities: Little Rock, Arkansas • Stanford, California • Fort Lauderdale, Florida + 106 more

Conditions: HIV Infections
Interventions: HIV screening strategies; Other
Lead sponsor: Westat; Other
Eligibility: 14 Years to 24 Years
Enrollment: 84,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 2 more

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa pegol; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 31
States / cities: Phoenix, Arizona • Long Beach, California • Sacramento, California + 26 more

Conditions: Melanoma, Metastatic Melanoma
Interventions: Vemurafenib, Bevacizumab, Cobimetinib; Drug
Lead sponsor: Melanoma Research Foundation Breakthrough Consortium; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 14
States / cities: Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Retinal Vein Occlusion
Interventions: AKB-9778; Drug
Lead sponsor: Aerpio Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Participants
Interventions: Rosuvastatin, ALXN2040; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Neoplasm of Uncertain Malignant Potential, Prolymphocytic Leukemia, Secondary Acute Myeloid Leukemia, T-Cell Large Granular Lymphocyte Leukemia
Interventions: Cytology Specimen Collection Procedure; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 2,545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 175
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 132 more

Conditions: Locally Advanced Hepatocellular Carcinoma
Interventions: Cabozantinib, Nivolumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care

Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely

Genome Transplant Dynamics

Examination of the Dynamic Relationships of Sleep, Physical Activity, and Circadian Rhythmicity With Neurobehavioral Heterogeneity in ADHD

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes

Preserving Ability Through Virtual Exercise (PAVE)

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

Oral Nicotine Pouch Marketing Features Influence on Perceptions

Reinforcement-Based Treatment for Pregnant Drug Abusers

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Hormone Therapy in Treating Patients With Prostate Cancer

Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study)

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

A Study on the Effect of High-Calorie Infant Formula on Growth and Nutrition in HIV-Infected Infants

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Screen2Prevent (S2P)

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO

Potential Drug Interaction Between ALXN2040 and Rosuvastatin

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)